Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Yamaoka Tojo, Minako ^a   Tojo, Taiki ^b   Takahira, Naonobu ^a   Matsunaga, Atsuhiko ^a   Aoyama, Naoyoshi ^b   Masuda, Takashi ^a   Izumi, Tohru ^b  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; TRIACYLGLYCEROL; URIC ACID; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; PERIPHERAL CIRCULATION; RISK FACTOR; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE; ABDOMINAL OBESITY; AGED; BLOOD; CHI SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDY; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; JAPAN; MIDDLE AGED; PATHOPHYSIOLOGY; RISK; RISK ASSESSMENT; STATISTICAL MODEL; UPREGULATION;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FASTING; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; JAPAN; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, ABDOMINAL; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES; UP-REGULATION; URIC ACID; WAIST CIRCUMFERENCE;

EID: 77952028081     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-17     Document Type: Article

References (47)

1. Grundy SM. Metabolic syndrome pandemic. Arteriosclerosis, thrombosis, and vascular biology 2008, 28(4):629-636. 10.1161/ATVBAHA.107.151092, 18174459.
2. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112(17):2735-2752. 10.1161/CIRCULATIONAHA.105.169404, 16157765.
3. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. The Journal of clinical endocrinology and metabolism 2007, 92(2):399-404. 10.1210/jc.2006-0513, 17284640.
4. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH. The metabolic syndrome. Endocrine reviews 2008, 29(7):777-822. 10.1210/er.2008-0024, 18971485.
5. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288(21):2709-2716. 10.1001/jama.288.21.2709, 12460094.
6. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. The New England journal of medicine 1996, 334(6):374-381. 10.1056/NEJM199602083340607, 8538710.
7. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 2007, 115(11):1345-1353. 10.1161/CIRCULATIONAHA.106.655142, 17339551.
8. Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Current opinion in lipidology 1996, 7(3):167-171. 10.1097/00041433-199606000-00010, 8818515.
9. Coutinho Tde A, Turner ST, Peyser PA, Bielak LF, Sheedy PF, Kullo IJ. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. American journal of hypertension 2007, 20(1):83-89. 10.1016/j.amjhyper.2006.06.015, 17198917.
10. Servais A, Giral P, Bernard M, Bruckert E, Deray G, Isnard Bagnis C. Is serum cystatin-C a reliable marker for metabolic syndrome?. The American journal of medicine 2008, 121(5):426-432. 10.1016/j.amjmed.2008.01.040, 18456039.
11. Saleem U, Khaleghi M, Morgenthaler NG, Bergmann A, Struck J, Mosley TH, Kullo IJ. Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. The Journal of clinical endocrinology and metabolism 2009, 94(7):2558-2564. 10.1210/jc.2008-2278, 19366852.
12. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR. Glucagon-like peptide-1 is a physiological incretin in rat. The Journal of clinical investigation 1995, 95(1):417-421. 10.1172/JCI117671, 295450, 7814643.
13. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379(6560):69-72. 10.1038/379069a0, 8538742.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419. 10.1007/BF00280883, 3899825.
15. Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, Mabuchi H, Teramoto T, Sasaki J, Nakaya N, Itakura H, Ishikawa Y, Ouchi Y, Horibe H, Shirahashi N, Kita T. Prevalence of metabolic syndrome in the general Japanese population in 2000. Journal of atherosclerosis and thrombosis 2006, 13(4):202-208.
16. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-17-36: a physiological incretin in man. Lancet 1987, 2(8571):1300-1304. 10.1016/S0140-6736(87)91194-9, 2890903.
17. Holst JJ. The physiology of glucagon-like peptide 1. Physiological reviews 2007, 87(4):1409-1439. 10.1152/physrev.00034.2006, 17928588.
18. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132(6):2131-2157. 10.1053/j.gastro.2007.03.054, 17498508.
19. Bray GA. Gastrointestinal hormones and weight management. Lancet 2009, 374(9701):1606-16. 10.1016/S0140-6736(09)61560-9, 19853906.
20. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50(3):609-613. 10.2337/diabetes.50.3.609, 11246881.
21. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, Seino Y. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America 1999, 96(26):14843-14847. 10.1073/pnas.96.26.14843, 24735, 10611300.
22. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nature medicine 2002, 8(7):738-742. 10.1038/nm727, 12068290.
23. Tsukiyama K, Yamada Y, Yamada C, Harada N, Kawasaki Y, Ogura M, Bessho K, Li M, Amizuka N, Sato M, Udagawa N, Takahashi N, Tanaka K, Oiso Y, Seino Y. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Molecular endocrinology (Baltimore, Md) 2006, 20(7):1644-1651. 10.1210/me.2005-0187, 16469773.
24. Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y, Drucker DJ. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. The Journal of clinical investigation 2007, 117(1):143-152. 10.1172/JCI25483, 1705821, 17187081.
25. Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?. British journal of pharmacology 2009, 157(8):1340-1351. 10.1111/j.1476-5381.2009.00376.x, 19681866.
26. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109(8):962-965. 10.1161/01.CIR.0000120505.91348.58, 14981009.
27. Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. The American journal of cardiology 2007, 100(5):824-829. 10.1016/j.amjcard.2007.05.022, 17719327.
28. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54(1):146-151. 10.2337/diabetes.54.1.146, 15616022.
29. Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovascular drugs and therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy 2007, 21(4):253-256.
30. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. The Journal of pharmacology and experimental therapeutics 2006, 317(3):1106-1113. 10.1124/jpet.106.100982, 16489128.
31. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117(18):2340-2350. 10.1161/CIRCULATIONAHA.107.739938, 18427132.
32. Xie Y, Wang SX, Sha WW, Zhou X, Wang WL, Han LP, Li DQ, Yu DM. Effects and mechanism of glucagon-like peptide-1 on injury of rats cardiomyocytes induced by hypoxia-reoxygenation. Chinese medical journal 2008, 121(21):2134-2138.
33. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58(4):975-983. 10.2337/db08-1193, 2661586, 19151200.
34. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. The Journal of clinical endocrinology and metabolism 1986, 63(2):492-498. 10.1210/jcem-63-2-492, 3522621.
35. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. The Journal of clinical endocrinology and metabolism 2001, 86(8):3717-3723. 10.1210/jc.86.8.3717, 11502801.
36. Schirra J, Katschinski M, Weidmann C, Schafer T, Wank U, Arnold R, Goke B. Gastric emptying and release of incretin hormones after glucose ingestion in humans. The Journal of clinical investigation 1996, 97(1):92-103. 10.1172/JCI118411, 507066, 8550855.
37. Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG, Aylwin SJ. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. The British journal of surgery 2006, 93(2):210-215. 10.1002/bjs.5227, 16392104.
38. Goldfine AB, Mun EC, Devine E, Bernier R, Baz-Hecht M, Jones DB, Schneider BE, Holst JJ, Patti ME. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. The Journal of clinical endocrinology and metabolism 2007, 92(12):4678-4685. 10.1210/jc.2007-0918, 17895322.
39. le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG, Bloom SR. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Annals of surgery 2006, 243(1):108-114. 10.1097/01.sla.0000183349.16877.84, 1449984, 16371744.
40. Wickremesekera K, Miller G, Naotunne TD, Knowles G, Stubbs RS. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obesity surgery 2005, 15(4):474-481. 10.1381/0960892053723402, 15946424.
41. Fisman EZ, Tenenbaum A. A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovascular diabetology 2009, 8:38. 10.1186/1475-2840-8-38, 2723076, 19619327.
42. Gallwitz B. The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions. Rev Diabet Stud 2006, 3(4):208-216. 10.1900/RDS.2006.3.208, 1828283, 17487346.
43. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. The American journal of medicine 2009, 122(6 Suppl):S37-50. 10.1016/j.amjmed.2009.03.015, 19464427.
44. Unger RH. Reinventing type 2 diabetes: pathogenesis, treatment, and prevention. JAMA 2008, 299(10):1185-1187. 10.1001/jama.299.10.1185, 18334695.
45. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy?. Drugs 2008, 68(15):2131-2162. 10.2165/00003495-200868150-00005, 18840004.
46. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta psychiatrica Scandinavica 2009, 119(1):4-14. 10.1111/j.1600-0447.2008.01317.x, 19133915.
47. Pannacciulli N, Le DS, Salbe AD, Chen K, Reiman EM, Tataranni PA, Krakoff J. Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. NeuroImage 2007, 35(2):511-517. 10.1016/j.neuroimage.2006.12.035, 1991301, 17317222.